Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

NCT05996627

Status	RECRUITING
Phase	Phase 2
Sponsor	Fred Hutchinson Cancer Center
Enrollment	82 participants

Key Eligibility Criteria

Inclusion (20)

- At least one diagnostic or distinctive cGVHD manifestation(s), with a clinical diagnosis of cGVHD,but patients do not need to meet National Institute of Health (NIH) criteria for cGVHD
- If eye involvement only, cGVHD must be confirmed on exam by an ophthalmologist or optometrist
- No new immune suppressive therapy added within preceding 2 weeks prior to study enrollment for any indication
- Continuation of agents previously given as either GVHD prophylaxis or acute/late acute GVHD therapy are permitted. Modification of dose of these agents for targeting of therapeutic drug levels is permitted, as are decreases in existing prednisone or prednisone equivalent dose based on routine clinical tapering practices. Increases in prednisone or prednisone equivalents are not allowed in the 2 weeks prior to enrollment
- Age 18 and older

... and 15 more (see full listing online)

Exclusion (9)

- Any systemic immune suppressive treatment for cGVHD (topical or local therapies are allowed)
- Plan to start systemic immune suppressive therapy for cGVHD or increase steroid dose within 14 days after planned start of study medication
- mg/kg/day or higher prednisone or prednisone equivalent dose at time of screening
- History of non-compliance that in the investigator's opinion would interfere with study participation
- Uncontrolled psychiatric illness

... and 4 more (see full listing online)

Locations (4 total)

Moffitt Cancer Center, Tampa, Florida, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
... and 1 more locations